Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

被引：7
|
作者：
Knox, Jennifer J.
Barrios, Carlos H.
Kim, Tae Min
Cosgriff, Thomas
Srimuninnimit, Vichien
Pittman, Kenneth B.
Sabbatini, Roberto
Rha, Sun Young
Flaig, Thomas W.
Page, Ray D.
Beck, J. Thaddeus
Cheung, Foon Yiu
Yadav, Sunil
Patel, Poulam M.
Geoffrois, Lionnel
Schiff, Edward
Niolat, Julie
Berkowitz, Noah
Voi, Maurizio
Motzer, Robert
机构：
[1] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] PUCRS Sch Med, Porto Alegre, RS, Brazil
[3] Seoul Natl Univ Hosp, Jongno Gu, South Korea
[4] East Jefferson Gen Hosp, Crescent City Res Consortium, Metairie, LA USA
[5] Siriraj Hosp, Bangkok, Thailand
[6] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
[7] AOU Policlin Modena, Modena, Italy
[8] Yonsei Univ Coll Med, Seoul, South Korea
[9] Univ Colorado Canc Ctr, Aurora, CO USA
[10] Ctr Canc & Blood Disorders, Ft Worth, TX USA
[11] Highlands Oncol Grp, Fayetteville, AR USA
[12] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China
[13] Univ Saskatchewan, Saskatoon Canc Ctr, Saskatoon, SK, Canada
[14] Univ Nottingham, Nottingham NG7 2RD, England
[15] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[16] Novartis Pharmaceut, E Hanover, NJ USA
[17] Novartis Pharma SAS, Rueil Malmaison, France
[18] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.4554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4554
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by Sunitinib versus first-line Sunitinib Followed by Everolimus in metastatic RCC (mRCC)
    Knox, Jennifer J.
    Barrios, Carlos H.
    Kim, Tae Min
    Cosgriff, Thomas
    Srimuninnimit, Vichien
    Pittman, Ken
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray D.
    Beck, J. Thaddeus
    Cheung, Foon-Yiu
    Yadav, Sunil
    Patel, Poulam
    Geoffrois, Lionel
    Schiff, Edward M.
    Niolat, Julie
    Berkowitz, Noah
    Voi, Maurizio
    Motzer, Robert J.
    [J]. BJU INTERNATIONAL, 2015, 116 : 15 - 15
  • [2] Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
    Knox, J. J.
    Barrios, C. H.
    Kim, T. M.
    Cosgriff, T.
    Srimuninnimit, V.
    Pittman, K.
    Sabbatini, R.
    Rha, S. Y.
    Flaig, T. W.
    Page, R. D.
    Beck, J. T.
    Cheung, F.
    Yadav, S.
    Patel, P.
    Geoffrois, L.
    Niolat, J.
    Berkowitz, N.
    Marker, M.
    Chen, D.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (06) : 1339 - 1345
  • [3] Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (vol 28, pg 1339, 2017)
    Knox, J. J.
    Barrios, C. H.
    Kim, T. M.
    Cosgriff, T.
    Srimuninnimit, V.
    Pittman, K.
    Sabbatini, R.
    Rha, S. Y.
    Flaig, T. W.
    Page, R. D.
    Beck, J. T.
    Cheung, F.
    Yadav, S.
    Patel, P.
    Geoffrois, L.
    Niolat, J.
    Berkowitz, N.
    Marker, M.
    Chen, D.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (11) : 2269 - 2269
  • [4] First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)
    Knox, J. J.
    Kay, A. C.
    Schiff, E.
    Hollaender, N.
    Rouyrre, N.
    Ravaud, A.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Final results of a non-interventional study with everolimus in mRCC after first-line therapy with sunitinib
    Bergmann, L.
    Goebell, P-J
    Kube, U.
    Kindler, M.
    Herrmann, E.
    Janssen, J.
    Schmitz, J.
    Weikert, S.
    Kloss, S.
    Steiner, G.
    Jakob, A.
    Staehler, M.
    Overkamp, F.
    Steiner, T.
    Guderian, G.
    Doehn, C.
    [J]. ONKOLOGIE, 2013, 36 : 7 - 8
  • [6] Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Barrios, Carlos H.
    Kim, Tae Min
    Falcon, Silvia
    Cosgriff, Thomas
    Harker, W. Graydon
    Srimuninnimit, Vichien
    Pittman, Ken
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray
    Bavbek, Sevil
    Beck, J. Thaddeus
    Patel, Poulam
    Cheung, Foon-yiu
    Yadav, Sunil
    Schiff, Edward M.
    Wang, Xufang
    Niolat, Julie
    Sellami, Dalila
    Anak, Oezlem
    Knox, Jennifer J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2766 - +
  • [7] Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC)
    Motzer, Robert John
    Barrios, Carlos H.
    Kim, Tae Min
    Falcon, Silvia
    Cosgriff, Thomas
    Harker, W. Graydon
    Pittman, Kenneth B.
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray D.
    Bavbek, Sevil E.
    Beck, J. Thaddeus
    Patel, Poulam M.
    Schiff, Edward
    Vaury, Alexandra
    Niolat, Julie
    Gogov, Sven
    Anak, Ozlem
    Knox, Jennifer
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Negrier, S.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] OVERALL SURVIVAL WITH SUNITINIB VERSUS INTERFERON (IFN)-ALFA AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
    Negrier, S.
    Figlin, R. A.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Huang, X.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 190 - 190
  • [10] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345